NEW YORK (GenomeWeb News) – Lab21 today announced an agreement with IntegraGen to develop a microRNA-based assay to identify colorectal cancer patients who may best respond to EGFR-inhibitor therapy.

Lab21 will develop an assay based on its SPARQ PCR technology to detect the expression levels of a miRNA biomarker called hsa-mir-31-3p. IntegraGen and its academic partners discovered and patented the biomarker, which has shown an ability to predict EGFR-inhibitor response in KRAS wild-type patients with metastatic colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.